We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » COVID Vaccine Makers Reject Offers to Expand Production Despite Citing Scale-Up as IP Waiver Alternative
COVID Vaccine Makers Reject Offers to Expand Production Despite Citing Scale-Up as IP Waiver Alternative
Although prominent COVID-19 vaccine makers have argued for ramping up production to help meet global vaccine needs as an alternative to waiving intellectual property (IP) rights, several pharma companies, including the world’s biggest generics maker, have been unable to secure such manufacturing arrangements.